Oncology

Latest News

NSCLC | Image: Lung Cancer Foundation of America

Zongertinib Shows Durable Responses With No Interstitial Lung Disease in HER2-Mutated Advanced NSCLC

By Mary Caffrey
Brooke McCormick

April 28th 2025

Results could give patients with HER2-mutated non–small cell lung cancer (NSCLC) an oral therapy option.

Considering the life-threatening risk of TLS, the researchers underscored the importance of identifying patients at particular risk of the complication. | Image credit: mi_viri - stock.adobe.com

Optimized Strategies Needed for TLS Prevention, Intervention in SCLC

By AJMC Contributor

April 23rd 2025

Diabetes monitoring | Image credit: abidika - stock.adobe.com

New-Onset Type 2 Diabetes Linked to Higher Cancer Risk

By Pearl Steinzor

April 23rd 2025

Vitamin D | Image credit: Galina Zhigalova - stock.adobe.com

Vitamin D’s Potential Role in Colorectal Cancer Prevention, Immune Health

By Pearl Steinzor

April 23rd 2025

The study highlighted symptom patterns in the short-term preceding ED visits and unplanned hospitalizations using a previously validated natural language processing a pipeline. | Image credit: Tyler Olson - stock.adobe.com

Symptom Documentation Differences in Acute Cancer Care Suggest Sociodemographic Disparities

By Rose McNulty

April 22nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

March 9th 2015

ASCO and PhRMA Critical of the CMS Oncology Care Model

One of the criticisms, which came from ASCO, points to the absence of consideration for patient heterogeneity that can result in physicians being penalized for providing patient-centered treatment.

March 9th 2015

Phase 2 Trial Defines Sunitinib Potential in Advanced Thyroid Cancer

While sunitinib failed as adjuvant treatment in advanced kidney cancer, this phase 2 study presented at the ongoing annual meeting of The Endocrine Society found that in patients with advanced thyroid cancer, sunitinib treatment resulted in median progression free survival of about 8 months. The authors think their results create sufficient evidence to initiate a phase 3 trial of the drug in thyroid cancer patients.

March 9th 2015

Oncology Clinic or Hospital, How Do Patients Decide?

New oncology payment models, 340B pricing and disproportionate share hospitals, and the significant difference in reimbursement rates for cancer care services are just some of the challenges faced by community oncology clinics. How do patients make informed decisions on where to go for care?

March 6th 2015

Study Underscores Harm From Unregulated Marketing of Genetic Tests

The study, conducted at the Dana-Farber Cancer Institute and published in the Journal of the National Cancer Institute found that the benefits of these personalized cancer products are reported much more frequently than are the limitations.

March 6th 2015

Phase 3 Melanoma Trial Reports Better 5-Year Survival With Ipilimumab

The study, published in the Journal of Clinical Oncology found that the 5-year survival with ipilimumab (18.2%) was double that with placebo (8.8%) and roughly double the historical survival rate of patients with stage IV melanoma (approximately 10%).

March 5th 2015

New Guidelines for Treating Pediatric Hodgkin Lymphoma Issued

A guideline has been issued that outlines the use of 3-D computed tomography-based radiation therapy planning and volumetric image guidance to more effectively treat pediatric Hodgkin lymphoma and to reduce the radiation dose to normal tissue, thus decreasing the risk of late side effects.

March 5th 2015

NCI to Begin Search for a New Director

Harold Varmus, MD, who has led the National Cancer Institute at the National Institutes of Health for nearly 5 years, announced today that he will step down from his post, effective March 31, 2015.

March 5th 2015

AbbVie to Buy Oncology Company Pharmacyclis

AbbVie will spend about $21 billion to buy leukemia drugmaker Pharmacyclics in its first major deal attempt since walking away from a $55 billion takeover of Shire last fall.

March 4th 2015

Nivolumab Approved for NSCLC

The FDA announced today that it has approved Opdivo (nivolumab) for use in NSCLC patients who have progressed on or after platinum-based chemotherapy.

March 4th 2015

Brain Tumor Patients Fare Poorly if Uninsured or on Medicaid, Study Reports

Brain tumor patients who are uninsured or use Medicaid stay hospitalized longer and develop more medical complications than those with private insurance, University of Florida Health researchers have found.

March 4th 2015

Multibillion Spent on Drug Development, But Is It Helping?

While the pharmaceutical industry has always justified the billions spent on developing a candidate drug molecule, the process has definitely seen some important changes. This article evaluates whether these revolutionary changes have influenced drug development for the better.

March 3rd 2015

Imaging Study Identifies Pre-Cancerous Changes in Breast Tissue

The technique, L-COSY, monitors biochemical changes in tissue and could improve the management of women at risk of breast cancer, such as those carrying mutations in BRCA1 and BRCA2.

March 3rd 2015

Study Evaluates Cost-Benefit of US Spending on Cancer Care

The study in Health Affairs published by Samir Soneji, PhD, an assistant professor at Dartmouth's Geisel School of Medicine and The Dartmouth Institute for Health Policy & Clinical Practice, found that despite a sharp rise in healthcare spending,caner mortality rates are very high in the US compared to Western Europe.

March 3rd 2015

Study Findings Validate the Use of Adjuvant Systemic Therapy in Gastrointestinal Tumors

The use of adjuvant systemic therapy for localized gastrointestinal stromal tumors has significantly increased over time, a new study published in the American Journal of Clinical Oncology, has found, and patients treated with the therapy have better survival than those treated with surgery alone, researchers say.

March 3rd 2015

Novation Survey Underscores Problems With Genetech's Specialty Drug Distribution Changes

The study found that following Genetech's decision to restrict the distribution of it's 3 popular cancer medications through specific specialty distributors, patient access to the drugs has reduced while costs have increased.

March 2nd 2015

Kyprolis Trumps Velcade in Multiple Myeloma Trial

Results released by Amgen, who bought the molecule from Onyx, show that Kyprolis yielded better results when used as second-line in relapsed patients.

March 2nd 2015

Web-Based Tool Designed to Improve Quality of Care in Thyroid Cancer

The Thyroid Cancer Clinical Registry is expected to improve quality of patient care as patient data would be readily available to all physicians involved in the patients care; however former Commission on Cancer chair Frederick L Greene, MD, wonders whether physicians would take the time to enter the clinical data into the system as required.

February 28th 2015

Urine Test for Bladder Cancer Could Aid Early Detection

A simple urine test could help to guide clinicians in the treatment of bladder cancer patients, researchers believe. Being able to reliably identify those patients with the most aggressive cancers early via urine tests, and expediting aggressive therapeutic strategies, may significantly improve outcomes, they say.

February 27th 2015

Opdivo Gets Priority Review for NSCLC

BMS announced in a press release today that Opdivo (nivolumab), approved for advanced melanoma, has received priority review from the FDA for treating patients with advanced NSCLC.

February 27th 2015

Studies Highlight Limitations in Emergency Provider Understanding of End-of-Life Care Choices

Emergency care providers vary in their understanding of a type of medical order intended to communicate seriously ill patients' choices for life-sustaining treatments, according to a pair of studies recently published.

February 27th 2015

AJMC Panel Sees Advantages in FDA Regulation of Molecular Diagnostic Tests for Cancer Care

The American Journal of Managed Care convened a discussion of 2 leading clinicians and 2 medical directors for leading payers, all of whom saw some merit in FDA's plans to bring oversight to the diagnostic testing market. The strongest advocate for greater FDA oversight was Daniel F. Hayes, MD, clinical director of the Breast Oncology Program at the University of Michigan, who will be a future president of the American Society of Clinical Oncology.

February 27th 2015

Community Oncology Alliance Announces Launch of Accreditation Pilot for OMH

Ten oncology practices around the nation will initiate their accreditation process this year, which includes an on-site survey bu the Commission on Cancer.

February 26th 2015

NICE Guidelines for Bladder Cancer Can Minimize Care Variance

NICE's first guideline on bladder cancer aims to improve the diagnosis and management of the seventh most common cancer in the UK.

February 26th 2015

Dr Ira Klein Discusses the CMS Oncology Care Model

The goals of the new CMS Oncology Care Model align very nicely with what payers want, according to Ira M. Klein, MD, MBA, FACP, national medical director, clinical thought leadership, office of the chief medical officer, Aetna.

February 26th 2015

Basket Trials Have FDA Support, But Will They Deliver?

Following the introduction of adaptive clinical trials, cancer researchers are now working on another revolutionary model, and they have the FDA's support in this effort. Named basket studies because they group different cancers together based on the driver mutation rather than the tumor of origin, these trials do not use the standard treatment as a control group, but look for a "Yes" or "No" response.

February 25th 2015

Fred Hutch Receives Multimillion Dollar Cancer Research Grant from PCORI

Project to research better way to treat neutropenia is 1 of 5 to get latest funding from Patient-Centered Outcomes Research Institute.

February 25th 2015

NICE Rejects Provenge, Says Treatment is Not Cost-Effective

The governing body for public health in the UK, National Institute for Health and Care Excellence, has refused to fund Provenge citing a high-price for the benefit the tretament provides. This may not be the best news for Valeant Pharmaceuticals which recently bought the regimen from the bankrupt Dendreon Corp.

February 24th 2015

Shared Decision-Making in Cancer Has Several Variables

A study published in the journal Cancer provides insights that may help physicians understand patients' preferences regarding their care, which may be crucial for optimizing patient participation in treatment decisions.

February 24th 2015

Study Results Could Improve Quality of Life in Pediatric ALL

The study, conducted in 2 separate patient cohorts at St. Jude Children's Hospital and the Children's Oncology Group and published in the The Journal of the American Medical Association, found that children with gene variants in the CEP72 gene were more sensitive to vincristine-induced peripheral neuropathy.

February 24th 2015

Study Warns Against Use of VEGF Inhibitors in Advanced Kidney Cancer

Interim analysis of a clinical trial evaluating adjuvant sorafenib, sunitinib or placebo in patients with advanced renal cell carcinoma found the recurrence rates and the disease-free survival were similar between all three treatment regimens.

...

135 136 137 138 139 140 141 142 143

...

184 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions